Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
128.63
-1.47 (-1.13%)
At close: Feb 20, 2026, 4:00 PM EST
128.76
+0.13 (0.10%)
After-hours: Feb 20, 2026, 6:19 PM EST
Neurocrine Biosciences Employees
Neurocrine Biosciences had 2,000 employees as of December 31, 2025. The number of employees increased by 200 or 11.11% compared to the previous year.
Employees
2,000
Change (1Y)
200
Growth (1Y)
11.11%
Revenue / Employee
$1,430,250
Profits / Employee
$239,300
Market Cap
12.91B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,000 | 200 | 11.11% |
| Dec 31, 2024 | 1,800 | 400 | 28.57% |
| Dec 31, 2023 | 1,400 | 200 | 16.67% |
| Dec 31, 2022 | 1,200 | 300 | 33.33% |
| Dec 31, 2021 | 900 | 55 | 6.51% |
| Dec 31, 2020 | 845 | 145 | 20.71% |
| Dec 31, 2019 | 700 | 115 | 19.66% |
| Dec 31, 2018 | 585 | 185 | 46.25% |
| Dec 31, 2017 | 400 | 204 | 104.08% |
| Dec 31, 2016 | 196 | 76 | 63.33% |
| Dec 31, 2015 | 120 | 26 | 27.66% |
| Dec 31, 2014 | 94 | 13 | 16.05% |
| Dec 31, 2013 | 81 | 3 | 3.85% |
| Dec 31, 2012 | 78 | 7 | 9.86% |
| Dec 31, 2011 | 71 | 5 | 7.58% |
| Dec 31, 2010 | 66 | 1 | 1.54% |
| Dec 31, 2009 | 65 | -60 | -48.00% |
| Dec 31, 2008 | 125 | -10 | -7.41% |
| Dec 31, 2007 | 135 | -132 | -49.44% |
| Dec 31, 2006 | 267 | -321 | -54.59% |
| Dec 31, 2005 | 588 | 203 | 52.73% |
| Dec 31, 2004 | 385 | 40 | 11.59% |
| Dec 31, 2003 | 345 | 69 | 25.00% |
| Dec 31, 2002 | 276 | 54 | 24.32% |
| Dec 31, 2001 | 222 | 34 | 18.09% |
| Dec 31, 2000 | 188 | 37 | 24.50% |
| Dec 31, 1999 | 151 | 2 | 1.34% |
| Dec 31, 1998 | 149 | 41 | 37.96% |
| Dec 31, 1997 | 108 | 5 | 4.85% |
| Dec 31, 1996 | 103 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Teva Pharmaceutical Industries | 33,950 |
| Viatris | 32,000 |
| Dr. Reddy's Laboratories | 27,811 |
| Elanco Animal Health | 9,450 |
| Amneal Pharmaceuticals | 8,300 |
| Alkermes | 1,800 |
| Hims & Hers Health | 1,637 |
| United Therapeutics | 1,305 |
NBIX News
- 7 days ago - Neurocrine Biosciences: Growth Beyond Just Ingrezza - Seeking Alpha
- 8 days ago - Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance - Benzinga
- 8 days ago - Neurocrine Biosciences: Expanding Opportunities, 2026 Will Be Less Exciting - Seeking Alpha
- 9 days ago - Neurocrine Biosciences, Inc. (NBIX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 - PRNewsWire
- 25 days ago - Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia - PRNewsWire
- 4 weeks ago - Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results - PRNewsWire
- 5 weeks ago - Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR - PRNewsWire